86791-04-0

Basic information

• Product Name: Diethyl (4-chlorobutyl)phosphonate
• Synonyms: Diethyl (4-chlorobutyl)phosphonate
• CAS NO: 86791-04-0
• Molecular Formula: C₈H₁₈ClO₃P
• Molecular Weight: 228.653481
• Mol File: 86791-04-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Diethyl (4-chlorobutyl)phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl (4-chlorobutyl)phosphonate(86791-04-0)
• EPA Substance Registry System: Diethyl (4-chlorobutyl)phosphonate(86791-04-0)

Safety Data

• Hazardous Substances Data: 86791-04-0(Hazardous Substances Data)

Upstream product

• 6940-78-9 4-chlorobutyl bromide 
• 74-96-4 ethyl bromide 
• 762-04-9 Diethyl phosphonate 
• 762-04-9 phosphonic acid diethyl ester 
• 110-56-5 1,4-dichlorobutane 

Downstream Products

• 190262-10-3 Diethyl [4-(7-benzyl-3-methylxanthin-1-yl)butyl]phosphonate 
• 190262-74-9 Diethyl [4-(1-benzyl-3-methylxanthin-7-yl)butyl]phosphonate 
• 190262-91-0 diethyl [4-(7-benzyl-3-ethylxanthin-1-yl)butyl]phosphonate 

Relevant articles and documents

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula STR1 where R1 and R3 are identical or different and at least one of the radicals R1 and R3 is a radical of the formula XI STR2 in which E is a covalent bond or a (C1 -C5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.